Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.72 |
| ▸ | POLB | P06746 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CETP | P11597 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15621420 | 0.84 | PDK1 (0.69) | LMNAPOLBMAPTMAPK1KMT2A | |
| SCHEMBL29524443 | 0.84 | PDK1 (0.68) | LMNAPOLBALDH1A1HPGDKMT2A | |
| SCHEMBL3535796 | 0.84 | PDK1 (0.68) | LMNAPOLBALDH1A1HPGDKMT2A | |
| SCHEMBL6352865 | 0.83 | PDK1 (0.76) | LMNAPOLB | |
| SCHEMBL3793230 | 0.83 | PDK1 (0.55) | LMNAPOLBALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2093177 | 0.82 | MAPT (0.71) | LMNAPOLBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3785961 | 0.82 | CETP (0.58) | LMNAPOLBALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2093176 | 0.80 | MAPT (0.69) | LMNAPOLBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL476919 | 0.80 | LMNA (0.69) | LMNAPOLBMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL14631798 | 0.79 | SMN1; SMN2 (0.56) | LMNAPOLBMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673948-B2 | Chemical compounds | GlaxoSmithKline, LLC (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2079466-B1 | SUBSTITUTED INDOLE COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-8026262-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-20090264482-A1 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-22 | — | — | US | disclosed |
| US-7572820-B2 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | US | disclosed |
| EP-0205272-B1 | CINNOLINE DERIVATIVES | ICI AMERICAS INC. (US) | 1991-08-14 | — | — | EP | disclosed |
| US-4886800-A | Substituted cinnoline derivatives as CNS depressants | ICI AMERICAS INC. (US) | 1989-12-12 | — | — | US | disclosed |
| EP-0205272-A2 | Cinnoline derivatives | ICI AMERICAS INC. (US) | 1986-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264482-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | LMNA 4095/4885POLB 4296/4885MAPT 2977/4885 |
| US-20110301203-A1 | CHEMICAL COMPOUNDS | AR, NR5A1, ESRRA | LMNA 4095/4885POLB 4296/4885MAPT 2977/4885 |
| US-20080139631-A1 | 3-(2-methyl-4-(trifluoromethyl)-5-cyano-indol-1-yl-methyl)-5-(3-(trifluoromethyl)phenyl)-1,2,4-oxadiazole or salt thereof; hypogonadism, sarcopenia, osteoporosis, wasting diseases, cancer cachexia, frailty, prostatic hyperplasia, prostate cancer, breast cancer; selective androgen receptor modulators | AR, NR5A1, NR3C2 | LMNA 3907/4885POLB 4293/4885MAPT 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.